Latency reversal and viral clearance to cure HIV-1

Author:

Margolis David M.12,Garcia J. Victor2,Hazuda Daria J.3,Haynes Barton F.4

Affiliation:

1. University of North Carolina HIV Cure Center, Department of Medicine, and Center for AIDS Research, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.

2. Department of Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.

3. Merck Research Laboratories, White Horse Junction, PA, USA.

4. Duke Human Vaccine Institute, Department of Medicine, and Department of Immunology, Duke University School of Medicine, Durham, NC, USA.

Abstract

Next steps toward curing HIV-1 Since the discovery of HIV-1 more than 30 years ago, prevention and treatment strategies have dominated the research agenda. More recently, however, scientists are also focusing their efforts toward finding a cure. Margolis et al. review an approach that involves HIV-1 latency reversal and viral clearance. The idea is to reactivate any dormant virus and coax it to produce viral proteins that the immune system can recognize. By combining a latency reversal strategy with immunotherapies, the body might be able to rid itself of all infected cells. Science , this issue p. 362

Funder

National Institutes of Health

Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery

University of North Carolina Center for AIDS Research

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference113 articles.

1. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic

2. UNAIDS 2015. Countries adopt UNAIDS Fast-Track Strategy to double number of people on life-saving HIV treatment by 2020; www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/november/20151124_LocationPopulation.

3. Long-Term Control of HIV byCCR5Delta32/Delta32 Stem-Cell Transplantation

4. Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient

5. Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation

Cited by 194 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Advancing Toward a Human Immunodeficiency Virus Cure;Infectious Disease Clinics of North America;2024-09

2. Effective in vivo reactivation of HIV-1 latency reservoir via oral administration of EK-16A-SNEDDS;European Journal of Pharmaceutics and Biopharmaceutics;2024-08

3. Transcriptional landscape of long non-coding RNAs (lncRNAs) and its implication in viral diseases;Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms;2024-06

4. CRISPR/CAS as a Powerful Tool for Human Immunodeficiency Virus Cure: A Review;AIDS Research and Human Retroviruses;2024-06-01

5. Ripretinib inhibits HIV-1 transcription through modulation of PI3K-AKT-mTOR;Acta Pharmacologica Sinica;2024-04-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3